Elhami Anis, Mobed Ahmad, Soleimany Reza, Yazdani Yalda, Kazemi Esmat Sadat, Mohammadi Mahya, Saffarfar Hossein
Dentistry faculty Ahvaz Jundishapur University of Medical Sciences Ahvaz Iran.
Social Determinants of Health Research Center Tabriz University of Medical Sciences Tabriz Iran.
Anal Sci Adv. 2024 Oct 24;5(9-10):e202400029. doi: 10.1002/ansa.202400029. eCollection 2024 Oct.
Women diagnosed with late-stage ovarian cancer suffer a very high rate of mortality. Accordingly, it is imperative to detect and diagnose the disease as early as possible in its development. Achievement of this aim implies relatively large-scale screening of women at an age of clinical significance through assay of biomarkers for disease present in blood or serum. Biosensor detection offers an attractive technology for the automated detection of such species. Among several biomarkers that have been identified that are present in patients with ovarian cancer, the only one that is commonly tested for in clinical use is cancer antigen 125, which is considered to be a poor biomarker for the disease. Here, we describe several biosensors that developed in the past decade for the detection of ovarian cancer biomarkers such as CA125, human epididymis protein 4 (HE4) and apolipoprotein A1. The challenges presented by the fabrication of biosensor devices for detecting ovarian cancer and the limited number of biosensors developed for this purpose are discussed.
被诊断为晚期卵巢癌的女性死亡率极高。因此，在疾病发展过程中尽早检测和诊断该疾病至关重要。实现这一目标意味着要通过检测血液或血清中存在的疾病生物标志物，对具有临床意义年龄的女性进行相对大规模的筛查。生物传感器检测为自动检测此类物质提供了一种有吸引力的技术。在已确定的几种存在于卵巢癌患者体内的生物标志物中，临床常用检测的唯一一种是癌抗原125，而它被认为是该疾病较差的生物标志物。在此，我们描述了在过去十年中开发的几种用于检测卵巢癌生物标志物（如CA125、人附睾蛋白4（HE4）和载脂蛋白A1）的生物传感器。还讨论了用于检测卵巢癌的生物传感器装置制造所面临的挑战以及为此目的开发的生物传感器数量有限的问题。
